In a report released today, Neil Chatterji from B.Riley Financial reiterated a Buy rating on Hyperfine (HYPR – Research Report), with a price target of $3.50. The company’s shares closed yesterday at $2.35.
According to TipRanks, Chatterji is an analyst with an average return of -4.6% and a 25.40% success rate. Chatterji covers the Healthcare sector, focusing on stocks such as Silk Road Medical, Stereotaxis, and LifeMD.
Currently, the analyst consensus on Hyperfine is a Moderate Buy with an average price target of $3.50.
See the top stocks recommended by analysts >>
Based on Hyperfine’s latest earnings release for the quarter ending March 31, the company reported a quarterly revenue of $2.64 million and a GAAP net loss of $12.16 million. In comparison, last year the company earned a revenue of $1.51 million and had a GAAP net loss of $23.78 million
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
HealthCor Catalio Acquisition Corp is a blank check company.
Read More on HYPR:
